

Title (en)

Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders

Title (de)

Verwendung von Pipamperon und einem SNDRI, SNRI oder SSRI zur Behandlung von Stimmungs- oder Angststörungen

Title (fr)

Utilisation de pipamperone et d'un SNDRI, SNRI ou SSRI pour le traitement des troubles de l'humeur ou anxieux

Publication

**EP 1541197 B8 20090610 (EN)**

Application

**EP 04025035 A 20041021**

Priority

- EP 04025035 A 20041021
- EP 03447279 A 20031202
- EP 04447001 A 20040105
- EP 04447066 A 20040318

Abstract (en)

[origin: EP1541197A1] The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability - hypersensitivity - hyperaesthesia - dissociative phenomena - etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.

IPC 8 full level

**A61K 31/343** (2006.01); **A61K 45/00** (2006.01); **A61K 31/00** (2006.01); **A61K 31/4545** (2006.01); **A61P 25/00** (2006.01); **A61P 25/04** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01); **A61P 25/20** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 43/00** (2006.01); **G01N 33/48** (2006.01)

CPC (source: EP)

**A61K 31/00** (2013.01); **A61K 31/343** (2013.01); **A61K 31/4545** (2013.01); **A61P 25/00** (2018.01); **A61P 25/04** (2018.01); **A61P 25/14** (2018.01); **A61P 25/16** (2018.01); **A61P 25/20** (2018.01); **A61P 25/22** (2018.01); **A61P 25/24** (2018.01); **A61P 25/28** (2018.01); **A61P 43/00** (2018.01)

Cited by

US9457018B2; EP2258357A3; CN113181183A; EP2236138A1; US2012202796A1; US8598235B2; US7855195B2; US7671056B2; WO2011069075A3; WO2008030651A1; WO2006083204A1; US7371822B2; US8198268B2; WO2010026154A1; WO2006016192A3; WO2007146073A3; WO2021139874A1; WO2021140103A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**EP 1541197 A1 20050615**; **EP 1541197 B1 20090318**; **EP 1541197 B8 20090610**; AT E425752 T1 20090415; CY 1110316 T1 20150114; DE 602004020042 D1 20090430; DK 1541197 T3 20090615; ES 2323269 T3 20090710; JP 2005194263 A 20050721; JP 4571485 B2 20101027; PL 1541197 T3 20091030; PT 1541197 E 20090604; SI 1541197 T1 20090831

DOCDB simple family (application)

**EP 04025035 A 20041021**; AT 04025035 T 20041021; CY 091100533 T 20090519; DE 602004020042 T 20041021; DK 04025035 T 20041021; ES 04025035 T 20041021; JP 2004349085 A 20041104; PL 04025035 T 20041021; PT 04025035 T 20041021; SI 200431110 T 20041021